The PPS during that particular quarter was between .05 before the company officially announced it was profitable and .08 after it announced profitability. The point here is that the company's PPS was around .08 when it announced it was profitable that one single solitary quarter before the Lodrane 24 was pulled. The company is not profitable yet. There are other ways to look at this but since PPS is what matters to you most. That is how I am looking at this for now.
So dilution is the tactic of the day? The change in share count is from the conversion of the preferred to common. Which means less dilution actually as shares are not paid for interest and all has been in place since 2009. Any way prattle on....
That's why I keep referring to market cap which takes into account the share count
Its really simple
35m market cap 2 15k square foot DEA FDA GMP approved mfg facilities 6 FDA approved drugs Soon to be 8 FDA approved drugs Then not too long 10 FDA approved drugs 4 Products with major partners in scaleup or development. Numerous other products with Epic.
And then the abuse line which will be ANDAs and NDAs, branded for Elite and these are entering trials this fiscal year.
Market Data 
Markets 
AI
